Emerging drugs for bipolar disorder-Reference-Cited by-同舟云学术

Emerging drugs for bipolar disorder

Published:2010-05-20 Issue:3 Volume:15 Page:453-466
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Sanches Marsal,Newberg Andrew R,Soares Jair C

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14728214.2010.492393

Reference96 articles.

1. Can brain-imaging studies provide a ‘mood stabilizer signature?’

2. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th edition. American Psychiatric Association, Washington, DC; 2000

3. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

4. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication

5. Screening for Bipolar Disorder in the Community

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammation and Metabolic Issues in Mood Disorders;Clinical Textbook of Mood Disorders;2024-05-30

2. Novel experimental and early investigational drugs for the treatment of bipolar disorder;Expert Opinion on Investigational Drugs;2021-11-02

3. New agents and perspectives in the pharmacological treatment of major depressive disorder;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2021-03

4. Prevention of Bipolar Disorder: Are We Almost There?;Current Behavioral Neuroscience Reports;2020-03-07

5. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial;Neuropsychobiology;2019